Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Key Points

• Director Anne Mcgeorge sold 7,750 Dianthus Therapeutics shares for approximately $844,828, reducing her direct ownership by 86.11% to 1,250 shares.
• DNTH shares traded at $108.49, near their 12-month high of $114.55. The company reported a quarterly loss of $0.90 per share, missing estimates, while revenue of $0.76 million exceeded expectations.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $124.27 price target; institutional investors own 47.53% of the stock.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) Director Anne Mcgeorge sold 7,750 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the transaction, the director directly owned 1,250 shares in the company, valued at $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Dianthus Therapeutics Price Performance

DNTH stock traded down $3.31 during trading on Tuesday, hitting $108.49. The stock had a trading volume of 777,875 shares, compared to its average volume of 972,407. Dianthus Therapeutics, Inc. has a twelve month low of $19.00 and a twelve month high of $114.55. The stock has a market capitalization of $5.93 billion, a P/E ratio of -26.14 and a beta of 1.22. The company's 50-day moving average price is $95.17 and its two-hundred day moving average price is $81.36.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Horizon Corp purchased a new position in Dianthus Therapeutics during the first quarter worth about $32,000. Global Retirement Partners LLC purchased a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $93,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at approximately $27,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $64,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on DNTH. Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush upped their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source